製品名:4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine

IUPAC Name:4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine

CAS番号:876343-10-1
分子式:C6H3ClIN3
純度:95%+
カタログ番号:CM104043
分子量:279.47

包装単位 有効在庫 価格(USD) 数量
CM104043-5g in stock ŌǙƚ
CM104043-10g in stock ŮIJŤ
CM104043-25g in stock ǙIJƚ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:876343-10-1
分子式:C6H3ClIN3
融点:-
SMILESコード:ClC1=C2C=C(I)NC2=NC=N1
密度:
カタログ番号:CM104043
分子量:279.47
沸点:
MDL番号:MFCD11518919
保管方法:-20°C

Category Infos

Pyrrolopyrimidines
Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.

Column Infos

BMF-219
Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.

Related Products